US EditionCVS drops Zepbound from preferred coverage in major blow to Eli Lilly
- On May 1, 2025, CVS Health announced it will drop Eli Lilly's weight-loss drug Zepbound from its standard formulary starting July 1 in the U.S.
- CVS prioritized Novo Nordisk's Wegovy and Saxenda as preferred drugs due to negotiated discounts and easing drug shortages affecting coverage decisions.
- Zepbound and Wegovy, both GLP-1 receptor agonists used for obesity treatment, have seen soaring popularity despite patchy coverage driven by cost and supply issues.
- Zepbound's first-quarter sales rose from $517 million to $2.3 billion year-over-year, but Lilly’s shares fell nearly 11%, closing at $804.06 Thursday afternoon.
- The formulary change may complicate patient access to Zepbound and could force Lilly to reduce prices to regain coverage amid strong competition from Novo.
Insights by Ground AI
Does this summary seem wrong?
36 Articles
36 Articles
All
Left
5
Center
24
Right
4
ThePatriotLight - "Strong Demand" For Lilly's Weight-Loss Drug Overshadowed By Guidance Cut, Shares Fall
ThePatriotLight - Eli Lilly & Co. shares fell in premarket trading in New York after the company slashed its full-year profit outlook, citing increased research and development expenses, despite posting first-quarter revenue and earnings that beat analysts' expectations, driven by strong demand for its anti-obesity drug, Mounjaro.Goldman analysts, including Asad Haider, provided clients with a first take on Lilly's first-quarter earnings, indica…
Coverage Details
Total News Sources36
Leaning Left5Leaning Right4Center24Last UpdatedBias Distribution73% Center
Bias Distribution
- 73% of the sources are Center
73% Center
15%
C 73%
12%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
